The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies

Oncogene

Volumn 27, Issue 9, 2008, Pages 1281-1289

  Gast, D ^a   Riedle, S ^a   Issa, Y ^a   Pfeifer, M ^a   Beckhove, P ^a   Sanderson, M P ^a   Arlt, M ^b   Moldenhauer, G ^a   Fogel, M ^c   Kruger A ^b   Altevogt, P ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Cell migration; Signaling; Therapeutic antibodies; Tumor growth

Indexed keywords

AMINO ACID; ANTIBODY; BETA3 INTEGRIN; CATHEPSIN B; L1 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE L1; PROTEIN ANTIBODY; SCLEROPROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL ASSAY; CELL MIGRATION; CELL MOTILITY; CELL MUTANT; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEURAL CELL ADHESION MOLECULE L1; PROTEIN STRUCTURE, TERTIARY;

MUS;

EID: 39749174412     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210747     Document Type: Article

References (31)

1. Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H. (2005). The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res 11: 1190-1197.
2. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J et al. (2006). Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 66: 936-943.
3. Bar-Eli M. (2001). Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 14: 78-85.
4. Brunner G, Reimbold K, Meissauer A, Schirrmacher V, Erkell LJ. (1998). Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasmino gen activation. Exp Cell Res 239: 301-310.
5. Cheng L, Itoh K, Lemmon V. (2005a). L1-mediated branchingis regulated by two ezrin-radixin-moesin (ERM)-binding sites, the RSLE region and a novel juxtamembrane ERM-binding region. J Neurosci 25: 395-403.
6. Cheng L, Lemmon S, Lemmon V. (2005b). RanBPM is an L1-interacting protein that regulates L1-mediated mitogen-activated protein kinase activation. J Neurochem 94: 1102-1110.
7. Colucci-D'Amato L, Perrone-Capano C, diPorzio U. (2003). Chronic activation of ERK and neurodegenerative diseases. Bioessays 25: 1085-1095.
8. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A et al. (2003a). L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 362: 869-875.
9. Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu DA, Tilgen Wet al. (2003b). L1 adhesion molecule (CD171) in development and progression of human malignant melanoma. Cancer Lett 189: 237-247.
10. Gast D, Riedle S, Schabath H, Schlich S, Schneider A, Issa Y et al. (2005). L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int J Cancer 115: 658-665.
11. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T et al. (2005). L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642.
12. Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Gast D, Joumaa S et al. (2003). ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J 17: 292-294.
13. Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K, Altevogt P. (2000). Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 275: 15490-15497.
14. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M. (2006). Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Human Pathol 37: 1000-1008.
15. Ignelzi MA, Miller DR, Soriano P, Maness PF. (1994). Impaired neurite outgrowth of src-minus cerebellar neurons on the cell adhesion molecule L1. Neuron 12: 873-884.
16. Knogler K, Grunberg J, Zimmermann K, Cohrs S, Honer M, Ametamey S et al. (2007). Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res 13: 603-611.
17. Lotan R. (1996). Retinoids in cancer chemoprevention. FASEB J 10: 1031-1039.
18. Mechtersheimer S, Gutwein P, Agmon LN, Stoeck A, Oleszewski M, Riedle S et al. (2001). Ectodomain sheddingof L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155: 661-674.
19. Meier F, Busch S, Gast D, Goppert A, Altevogt P, Maczey E et al. (2006). The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer 119: 549-555.
20. Moldenhauer G, Momburg F, Moller P, Schwartz R, Hammerling GJ. (1987). Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 56: 714-721.
21. Moos M, Tacke R, Scherer H, Teplow D, Fruh K, Schachner M. (1988). Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 334: 701-703.
22. Primiano T, Baig M, Maliyekkel A, Chang BD, Fellars S, Sadhu J et al. (2003). Identification of potential anticancer drugtarg ets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 4: 41-53.
23. Schaefer AW, Kamiguchi H, Wong EV, Beach CM, Landreth G, Lemmon V. (1999). Activation of the MAPK signal cascade by the neural cell adhesion molecule L1 requires L1 internalization. J Biol Chem 274: 37965-37973.
24. Schaeffer HJ, Weber MJ. (1999). Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444.
25. Schmid RS, Pruitt WM, Maness PF. (2000). A MAP kinase-signaling pathway mediates neurite outgrowth on L1 and requires Src-dependent endocytosis. J Neurosci 20: 4177-4188.
26. Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB. (2006). Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scatteringand motility of MCF7 breast carcinoma cells. Cancer Res 6: 11370-11380.
27. Senner V, Kismann E, Puttmann S, Hoess N, Baur I, Paulus W. (2002). L1 expressed by glioma cells promotes adhesion but not migration. Glia 38: 146-154.
28. Silletti S, Yebra M, Perez B, Cirulli V, McMahon M, Montgomery AM. (2004). Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem 279: 28880-28888.
29. Tang N, He M, O'Riordan MA, Farkas C, Buck K, Lemmon V et al. (2006). Ethanol inhibits L1 cell adhesion molecule activation of mitogen-activated protein kinases. J Neurochem 96: 1480-1490.
30. Thelen K, Kedar V, Panicker AK, Schmid RS, Midkiff BR, Maness PF. (2002). The neural cell adhesion molecule L1 potentiates integrin-dependent cell migration to extracellular matrix proteins. J Neurosci 22: 4918-4931.
31. Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G et al. (2002). Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer 38: 1708-1716.